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Abstract
During a period of 6 years and 5 months (January 1999 to May 2005), 103 extended-spectrum b-lactamase (ESBL)-producing Klebsiella
pneumoniae isolates, each from an individual patient or site, were collected at Mongi Slim University Hospital Centre, Tunis, Tunisia.
The objectives of our work were the characterization of the bla genes encoding ESBLs, the investigation of clonal diversity of strains,
and identiﬁcation of the transmission modes of the resistance genes. We carried out detection by PCR and sequencing of the blaSHV,
blaCTX-M and blaTEM genes, transferability studies, plasmid replicon typing, and analysis by multilocus sequence typing (MLST) on selected
isolates. Forty-seven isolates were found to be producers of CTX-M-type ESBLs, of which 43 were CTX-M-15, two CTX-M-14 and
two CTX-M-27. Fifty-eight isolates were producers of SHV-12, and three were producers of SHV-2a. More than one ESBL was
detected in seven isolates, as ﬁve produced both CTX-M-15 and SHV-12, and two produced both CTX-M-27 and SHV-12. By a PCR-
based replicon typing method, the plasmids carrying the blaSHV-2a or blaCTX-M-15 genes were assigned to IncFII or, more rarely, to IncL/
M types. Of 12 plasmids carrying the blaSHV-12 gene, only one could be typed: it was positive for the HI2 replicon. The MLST results
showed large genetic background diversity in the SHV-12-producing isolates and dissemination of speciﬁc clones of the CTX-M-15-pro-
ducing isolates within the same ward and among wards, and suggested endemicity with horizontal dissemination of the blaCTX-M-15 and
the blaSHV-12 genes.
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Introduction
Extended-spectrum b-lactamases (ESBLs) have increased dra-
matically in prevalence among clinical isolates of Enterobacteri-
aceae during these last three decades. These enzymes are
the major source of resistance to penicillins and oxyimino-
cephalosporins in Enterobacteriaceae. ESBLs are most often
derivatives of the TEM or SHV families, although other unre-
lated enzyme groups, such as CTX-M, PER, GES, VEB and
OXA, have also been described [1]. ESBLs are most com-
monly detected in Klebsiella pneumoniae, a cause of signiﬁcant
community-acquired and hospital-acquired infections [1,2]. In
Tunisia, ESBL-producing K. pneumoniae has been described as
one of the most important pathogens causing serious ende-
mic and epidemic nosocomial infections, especially in neona-
tal units [3–5]. The detected prevalence of this multidrug-
resistant strain in Tunisian hospitals varies from 10% to
32.4%, with a high incidence (87.5%) in paediatric intensive-
care units [4,6,7]. ESBLs have also been found in other spe-
cies of Enterobacteriaceae causing nosocomial outbreaks in
Tunisia [8,9]. The SHV-2 enzyme was the ﬁrst ESBL to be
isolated, in 1984 from a K. pneumoniae strain in Tunisia
[10]. Recently, SHV-12, SHV-2a, CTX-M-27, CTX-M-28,
CTX-M-15 and CTX-M-16 have been described in
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Tunisian hospitals [3,6,8,9,11]. Moreover, ESBLs have also
been reported in Escherichia coli strains of food origin in
Tunisia, including CTX-M-1, CTX-M-8, CTX-M-14 and
SHV-5 [12].
The aims of the present study were the characterization
of the bla genes encoding ESBLs, the investigation of clonal
diversity in the isolates and the identiﬁcation of the transmis-
sion modes of the resistance genes among ESBL-producing
K. pneumoniae isolates in Mongi Slim University Hospital
Centre, in the northern part of Tunisia.
Materials and Methods
Hospital setting
Mongi Slim University Hospital Centre is a general hospital
with 220 beds, situated in the northern region of Tunis,
Tunisia. It comprises different wards: Paediatric (with a neo-
natal unit), Gynaecology–Obstetric, General Surgery, Inten-
sive-care Unit, Cardiology, Internal Medicine, and
Rheumatology–Acupuncture.
Bacterial strains
In total, 1280 K. pneumoniae isolates (841 from inpatients
and 439 from outpatients) were collected at the clinical labo-
ratory of Mongi Slim University Hospital Centre between
January 1999 and May 2005. Among these, 103 ESBL-produc-
ing K. pneumoniae isolates, each from an individual patient or
site, were detected. These consisted of 101 clinical isolates
and two isolates from the hospital environment (aspiration
reservoir and bed). Three of the 101 clinical ESBL-producing
K. pneumoniae isolates were obtained from three outpatients.
The incidence of ESBL producers was 7.89% (101/1280) of
all isolates and 11.65% (98/841) of isolates from hospitalized
patients.
Identiﬁcation
Identiﬁcation was performed with the API-20E system (bio-
Me´rieux, Marcy L’Etoile, France) and was conﬁrmed by
sequence analysis of the gene (rpoB) coding for the b-subunit
of RNA polymerase, as previously described [13].
Antibiotic susceptibility tests
The susceptibilities to antimicrobial agents were determined
by the disk diffusion method on Mueller–Hinton agar (Bio-Rad,
Marnes La Coquette, France), according to the guidelines of
the CLSI [14]. The following antibiotics were tested: amoxycil-
lin, ticarcillin, cefalothin, cefoxitin, cefotaxime, ceftazidime,
aztreonam, imipenem, streptomycin, gentamicin, tobramycin,
kanamycin, amikacin, chloramphenicol, tetracycline, trimetho-
prim–sulphamethoxazole and ciproﬂoxacin. Production of
ESBLs was detected by the double-disk synergy test with disks
of amoxycillin–clavulanic acid surrounded at a radius of 20 mm
by cefotaxime, ceftazidime and aztreonam.
PCR ampliﬁcation of antimicrobial resistance genes and
sequence analysis
The resistance genes blaTEM, blaSHV and blaCTX-M were ampli-
ﬁed by PCR as described previously [8,15,16]. PrIS26-F and
blaU4R primers were designed for speciﬁc detection of
ESBL-encoding blaSHV genes [17,18]. PrIS26-F was located in
the coding region of the transposase of IS26, which is
upstream of the promoter region of the blaSHV gene in such
structures [19,20].
Sequencing of PCR products was performed at the Institut
Pasteur, Genotyping of Pathogens and Public Health Unit.
The nucleotide sequences and the deduced protein
sequences were analysed with EditSeq and Megalign software
(Dnastar, Madison, WI, USA). The BLASTN program of
NCBI was used for database searches (http://www.ncbi.nlm.
nih.gov/BLAST/).
Exploration of the upstream sequence of the blaCTX-M and
blaSHV genes
The presence of ISEcp1 was investigated as previously
described [21]. Exploration of the upstream sequence of the
blaSHV gene was performed by PCR using PrIS26-F and SHV-
INT-R (5¢-GAT TTG CTG ATT TCG CTC GG-3¢) primers
[18]. PCR mixture and cycling conditions were as for the
blaCTX-M ampliﬁcation.
Transfer of resistance
Conjugation experiments were performed on 48 isolates
selected on the basis of year of isolation and type of
resistance (Table 1) as previously described [15]. E. coli
strain J53 RifR, E. coli strain C1A NalR or E. coli strain K12
AziR was used as recipient, as appropriate. Transconjugants
were selected on Trypticase soy (Bio-Rad) agar plates con-
taining ceftazidime (2 mg/L) or cefotaxime (4 mg/L) and
either rifampicin (250 mg/L), nalidixic acid (64 mg/L) or
sodium azide (500 mg/L). Transfer experiments using elec-
troporation were performed for 12 non-conjugative plas-
mids. Plasmid DNA was extracted by a lysis alkaline
procedure [22] and was transferred into electrocompetent
E. coli DH10B by standard electroporation techniques, with
a Micropulser electroporation apparatus (Bio-Rad). Trans-
formants were selected on Mueller–Hinton agar containing
cefotaxime (4 mg/L) or ceftazidime (2 mg/L). Transconju-
gants and transformants were submitted to bacterial identi-
ﬁcation with the API-20E system, antibiotic susceptibility
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testing and PCR ampliﬁcation of the antimicrobial resis-
tance genes mentioned above.
Plasmid analyses, Southern blotting and hybridization
Plasmid DNA from K. pneumoniae strains and their corre-
sponding E. coli transconjugants or transformants extracted
by an alkaline lysis method was analysed by electrophoresis
in 0.8% agarose gels as previously described [22,23]. Plasmid
DNA was digested with either EcoRI or PstI endonuclease
(Roche, Meylan, France), and the fragments were analysed as
previously described [16]. Southern blotting using blaSHV
(1060 bp) and blaCTX-M-15 (840 bp) PCR-generated probes
was performed as previously described [23], using ECL direct
nucleic acid labelling and detection systems (Amersham
Biosciences, Little Chalfont, UK). The blaU5F and blaU4R
primers were used to generate the blaSHV-12 probe [17]. The
content and size of plasmids were determined as described
by Barton et al. [24].
Plasmid replicon type determination
PCR-based replicon typing was performed on 21 conjugative
and non-conjugative plasmids (including three of group A), as
described by Carattoli et al. [25]. The 18 primer pairs targeting
FIA, FIB, FIC, HI1, HI2, I1-Ic, L/M, N, P, W, T, A/C, K, B/O, X, Y,
F and FII replicons were used in separate PCR reactions.
Multilocus sequence typing (MLST)
Analysis by MLST was performed as described previously
[13,26] (http://www.pasteur/fr/mlst) on 24 isolates selected
on the basis of year of isolation and type of ESBL (Table 1).
Results
Bacterial identiﬁcation
The rpoB sequences showed that 101 K. pneumoniae isolates
belonged to phylogroup Kp1 [27], and two ESBL-producing
isolates belonged to Kp2 and Kp6, respectively [17].
Antibiotic susceptibility tests
The disk diffusion method showed that all isolates were
resistant to all b-lactams used except for cefoxitin, and imip-
enem. Clinical isolates manifested high-level resistance to the
aminoglycosides kanamycin (94%), tobramycin (93%), genta-
micin (92%), amikacin (77%), and streptomycin (73%), to tet-
racycline (94%), and to trimethoprim–sulphamethoxazole
(72%). Resistance of the strains to ﬂuoroquinolones was also
remarkable (ciproﬂoxacin, 48.5%). The double-disk synergy
test was positive for the 103 isolates studied (data not
shown).
b-Lactamase gene characterization
PCR and sequence analysis revealed that 47 of 101 clinical
isolates had a blaCTX-M gene; of these, 43 of 47 had the
blaCTX-M-15 gene, two of 47 the blaCTX-M-14 gene, and two of
47 the blaCTX-M-27 gene. Analysis of SHV PCR products
showed that 58 of 101 clinical isolates had the blaSHV-12 gene,
and three of 101 the blaSHV-2a gene. Five of the 101 isolates
were found to carry the blaCTX-M-15 and blaSHV-12 genes (iso-
lates 40, 43, 44 and two others not listed in Table 1), and
two of 101 isolates had the blaCTX-M-27 and blaSHV-12 genes
(isolates 31 and 32). The blaTEM-1 gene was detected in 22 of
43 isolates (51%) containing the blaCTX-M-15 gene, and in 11
of 58 isolates (19%) containing the blaSHV-12 gene. The occur-
rence of the blaSHV-12 gene decreased over time, whereas
the blaCTX-M-15 gene became predominant from 2003 to
2005 (Fig. 1). Two isolates from the hospital environment
were found to contain the blaSHV-12 gene.
Exploration of the upstream sequence of the blaCTX-M and
blaSHV genes
The insertion sequence ISEcp1 was identiﬁed upstream of
the blaCTX-M gene in all but one of the isolates. This isolate
had the blaCTX-M-15 gene. The insertion sequence IS26 was
localized 73 bp upstream of all the blaSHV genes in the oppo-
site direction.
Transfer of resistance
Cefotaxime and ceftazidime resistance was successfully trans-
ferred by conjugation from 36 of the 48 isolates (75%). For
the 12 non-conjugative plasmids, the transfer of resistance to
the above antibiotics was obtained by electroporation of
plasmid DNA. We also observed co-transfer, following con-
jugation or electroporation, of resistance to other antibiot-
ics, such as i.e. streptomycin (51.6%), gentamicin (60%),
tobramycin (89%), kanamycin (89%), amikacin (50%),
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FIG. 1. Evolution of CTX-M-15 and SHV-12 incidence during the
study period.
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chloramphenicol (23%), tetracycline (75%) and trimetho-
prim–sulphamethoxazole (75.6%). Production of ESBLs was
detected in all transconjugants and transformants by the dou-
ble-disk synergy test. The presence of the ESBL gene was
conﬁrmed by PCR. Only the blaCTX-M gene was detected in
transconjugants corresponding to K. pneumoniae isolates in
which more than one ESBL was present.
Plasmid analyses, Southern blotting and hybridization
The analysis of transconjugants and transformants revealed
the presence of large plasmids (30–120 kb for CTX-M type;
60–200 kb for SHV type). Digestion with EcoRI of plasmid
DNA from transconjugants and the transformants producing
SHV-12-type b-lactamases classiﬁed them into 12 different
restriction proﬁle groups (Table 1; Fig. 2). Plasmids isolated
from transconjugants producing SHV-2a yielded two EcoRI
restriction proﬁles (Table 1 and data not shown). Hybridiza-
tion with a blaSHV-12 probe showed different plasmid EcoRI-
generated fragments (Fig. 2).
PstI digestion of plasmid DNA from transconjugants con-
taining blaCTX-M-27 yielded an identical restriction proﬁle
(Table 1 and data not shown). Plasmid ﬁngerprinting of
transconjugants and transformants of isolates producing
CTX-M-15 using PstI classiﬁed them in four groups (Fig. 3;
Table 1).
Plasmid replicon type determination
The replicons could not be determined for the blaSHV-12-car-
rying plasmids, except for the plasmid showing the restric-
tion proﬁle F and associated with the IncHI2 replicon
(Table 1). The plasmids carrying blaSHV-2a or blaCTX-M-15
were assigned to the FII and L/M replicon types (Table 1).
The blaCTX-M-15-carrying plasmid representing the restriction
proﬁle B was negative for all of the replicons tested, as well
as the blaCTX-M-27-carrying plasmid (Table 1).
MLST
When compared by MLST analysis, the 24 selected isolates
showed 15 different sequence types (STs) (Table 1). This
analysis showed the dissemination of speciﬁc CTX-M-15-pro-
ducing K. pneumoniae clones: ST101 and ST107 in the Inten-
sive-care Unit, and ST147 between the Intensive-care Unit
and the Paediatric Unit (Table 1).
On the other hand, the MLST analysis showed diversity
among the SHV-12-producing isolates, as the 15 tested iso-
lates showed 11 different STs: ST25, ST35, ST48, ST107,
ST133, ST309, ST320, ST321, ST323, ST324 and ST325
(Table 1). However, MLST analysis also showed dissemina-
tion of the speciﬁc clone ST321 between the Intensive-care
Unit and the Paediatric Unit and of the speciﬁc clone
ST309 in the Paediatric Unit (Table 1). We noted an evolu-
tion of resistance for some clones over time. For example,
the SHV-12-producing isolates 19 and 20, obtained in May
and November 2000, respectively, as well as CTX-M-15-
producing isolate 49, isolated in May 2005, showed the
same ST (ST321). The SHV-2a-producing isolates 28 and
29, whose plasmids showed different EcoRI restriction pro-
ﬁles and different replicons, manifested an indistinguishable
ST (ST322).
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FIG. 2. EcoRI restriction proﬁles of plasmids from transconjugants
producing SHV-12 enzymes and Southern hybridization with the
blaSHV-12 probe. Lanes: 1, Raoul marker (QBiogene, Illkirch, France);
2, Tc-17 (proﬁle S4); 3, Tc-16 (proﬁle S3); 4, Tc-18 (proﬁle I1); 5,
Tc-21 (proﬁle Q1); 6, 1-kb DNA ladder; 7, Tc-8 (proﬁle H4); 8, Tc-
20 (proﬁle N1); 9, Tc-19 (proﬁle I1); 10, Tc-4 (proﬁle E3); 11, Tc-2
(proﬁle E2); 12, Tc-13 (proﬁle S1); 13, Tc-1 (proﬁle E1); 14, Raoul
marker (QBiogene). For Tc-1, Tc-2, Tc-4, Tc-20 and Tc-16, the
presence of multiple positive hybridization signals of the blaSHV-12
gene is due to the presence of several copies of this gene in the
same plasmid (Table 1).
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Discussion
We noted a temporal shift in the prevalence of ESBL types
(Fig. 1). Thus, the CTX-M-type ESBLs have clearly been pre-
dominant during this last decade, as has been recently
described worldwide [28]. Some dominant SHV types con-
tinue to be important, especially SHV-12 [29]. SHV-12 and
SHV-2a were found in the isolates investigated. These
enzymes seem to be common not only in Tunisia but also in
many countries in north and central Africa [3,23].
MLST is well suited to characterizing the genetic relation-
ships between the organisms of bacterial species, including
Klebsiella spp. [13,26]. By this method, 375 STs are currently
distinguished among K. pneumoniae isolates (http://www.pas-
teur.fr/mlst/Kpneumoniae.html). This is the ﬁrst report using
MLST analysis for typing of K. pneumoniae isolates in Tunisia.
MLST analysis showed that two isolates containing the
blaSHV-2a gene were clonally related but possessed different
SHV-2a-carrying plasmids, whereas the isolates containing
the blaSHV-12 gene displayed chromosomal and plasmid diver-
sity, conﬁrming the results of our ﬁrst investigation [7]. Only
one of the blaSHV-12-carrying plasmid could be characterized
by replicon typing. Further research is necessary to provide
more information about these blaSHV-12-carrying plasmids.
The blaCTX-M-15 gene represented the most abundant
CTX-M allele (43 of 47 strains producing CTX-M) detected
in our study. The ﬁrst CTX-M-15 was described in India in
1999 [30], but this enzyme has now emerged in different
parts of the world, and seems to be the most recently
described ESBL type [16,28,31,32]. In Tunisia, dissemination
of CTX-M-15 has been reported in K. pneumoniae and E. coli
strains [6,9,33]. Recent reports indicate that worldwide dis-
semination of CTX-M-15 is mediated by clonally related
E. coli strains, particularly speciﬁc clones of phylogroup B2,
ST131, and phylogroup D, ST405) [31,33,34]. The successful
spread of CTX-M-15 seems to be also related to IncFII plas-
mids [31,33]. A few reports have characterized the Inc type
of the blaCTX-M-15-carrying plasmids disseminated in K. pneu-
moniae strains, and detected IncFII, IncFI or IncL/M types
[35,36]. The blaCTX-M-15-carrying plasmids studied here were
also assigned to incompatibility groups IncFII and IncL/M, sug-
gesting mobilization of this gene among different plasmid
scaffolds. All but one of the blaCTX-M genes studied here
were ﬂanked by the insertion sequence ISEcp1 on their 5¢-
side. ISEcp1 was identiﬁed in the vicinity of many blaCTX-M
genes, and it has been shown that this insertion sequence
mobilizes various b-lactamase genes, including the blaCTX-M-15
gene, to transfer between different replicons [21,30,37].
MLST analysis of our CTX-M-15-producing K. pneumoniae
isolates showed that dissemination of these resistant strains
is due to the spread of speciﬁc clones of ST42, ST107,
ST101, ST147, ST133 and ST321. Interestingly, a countrywide
dissemination of an ST147 ciproﬂoxacin-resistant CTX-M-15-
producing K. pneumoniae clone was described during a
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FIG. 3. PstI restriction proﬁles of plasmids from transconjugants or
electroporants producing CTX-M-15 enzymes and Southern hybrid-
ization with the blaCTX-M-15 probe. Lanes: 1, Raoul marker (QBio-
gene); 2, Tc-48 (proﬁle A3); 3, Tc-46 (proﬁle A1); 4, Tc-45
(proﬁle A4); 5, Ep-36 (proﬁle B5); 6, Tc-41 (proﬁle C1); 7, 1-kb
DNA ladder; 8, Tc-42 (proﬁle A3); 9, Ep-34 (proﬁle B4); 10, Ep-33
(proﬁle B3); 11, Ep-37 (proﬁle B2); 12, Ep-35 (proﬁle B1); 13, Tc-43
(proﬁle A2); 14, Raoul marker (QBiogene). The presence of multiple
positive hybridization signals of the blaCTX-M-15 gene is probably due
to the partial digestion of the plasmid carrying the blaCTX-M15 gene
(Tc-43 and Tc-45) or due to the presence of different plasmids in
the same preparation (Ep-34) (Table 1).
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national survey in Hungary in 2005 [32]. In our study, the
ﬁrst isolation of this speciﬁc clone was made in 2003.
We report here for the ﬁrst time the presence of the
blaCTX-M-14 gene in clinical isolates in Tunisia. Our study also
revealed that two isolates had the blaCTX-M-27 gene. This
gene had already been identiﬁed in isolates of Salmonella ent-
erica during a nosocomial neonatal outbreak in Tunisia [8].
The appearance of CTX-M-producing K. pneumoniae strains
at Mongi Slim University Hospital is probably due to the
importation of these multidrug-resistant strains, as their
occurrence has been described in other hospitals in Tunisia
[6,8,9,33].
In conclusion, the present article documents the emer-
gence of CTX-M b-lactamase-producing K. pneumoniae
strains in Tunisia and the decline of the SHV type. Tunisian
laboratories should have appropriate methods for detection
of this ESBL and of strains harbouring these enzymes.
Acknowledgements
This work was performed in the Biodiversity of Emerging
Bacterial Pathogens Unit, Institut Pasteur. We thank P. A. D.
Grimont for his support, L. Fabre for technical assistance in
plasmid analysis and hybridization, L. Sontag for a technical
contribution to replicon typing, nuclease S1 treatment and
PFGE analysis, and V. Gautier for technical assistance with
cloning experiments.
Transparency Declaration
This work was supported ﬁnancially by the Institut Pasteur
and a generous gift from the Conny-Maeva Charitable Foun-
dation. All authors declare no relationship (commercial or
otherwise) that may constitute a dual or conﬂicting interest.
References
1. Paterson DL, Bonomo RA. Extended spectrum b-lactamases: a clinical
update. Clin Microbiol Rev 2005; 18: 657–686.
2. Brisse S, Grimont F, Grimont PAD. The genus Klebsiella. In: Dworkin
M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E, eds. Prokary-
otes, 3rd edn. New York: Springer, 2006; 159–196.
3. Ben-Hamouda T, Foulon T, Ben-Mahrez K. Involvement of SHV-12
and SHV-2a encoding plasmids in outbreaks of extended-spectrum-b-
lactamase-producing Klebsiella pneumoniae in a Tunisian neonatal
ward. Microb Drug Resist 2004; 10: 132–138.
4. Ben Jaballah N, Bouziri A, Mnif K, Hamdi A, Khaldi A, Kchaou W.
Epidemiology of hospital-acquired bloodstream infections in a Tuni-
sian pediatric intensive care unit: a 2-year prospective study. Am J
Infect Control 2007; 35: 613–618.
5. Boutiba-Ben Boubaker I, Ghozzi R, Ben Abdallah H, Mamlouk K, Ka-
moun A, Ben Redjeb S. Evolution of acquired resistance to third-gen-
eration cephalosporins in Enterobacteriaceae in a Tunisian hospital
1993–2001. Clin Microbiol Infect 2004; 10: 665–670.
6. Abbassi MS, Torres C, Achour W et al. Genetic characterisation of
CTX-M-15-producing Klebsiella pneumoniae and Escherichia coli strains
isolated from stem cell transplant patients in Tunisia. Int J Antimicrob
Agents 2008; 32: 308–314.
7. Elhani D, Bakir L, Aouni M. Dissemination of an extended spectrum
beta-lactamase producing Klebsiella pneumoniae strains in a Tunisian
university hospital center [in French]. Ann Biol Clin 2006; 64: 237–243.
8. Boualle`gue-Godet O, Ben Salem Y, Fabre L et al. Nosocomial out-
break caused by Salmonella enterica serotype Livingstone producing
CTX-M-27 extended-spectrum b-lactamase in a neonatal unit in
Sousse, Tunisia. J Clin Microbiol 2005; 43: 1037–1047.
9. Mamlouk K, Boutiba-Ben Boubaker I, Gautier V et al. Emergence and
outbreaks of CTX-M beta-lactamase-producing Escherichia coli and
Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol
2006; 44: 4049–4056.
10. Philippon A, Ben Redjeb S, Fournier G, Ben Hassen A. Epidemiology
of extended spectrum b-lactamases. Infection 1989; 17: 347–354.
11. Ben Achour N, Mercuri PS, Power P et al. First detection of CTX-M-
28 in a Tunisian hospital from a cefotaxime-resistant Klebsiella pneu-
moniae strain. Patho Biol (Paris) 2009; 57: 343–348.
12. Jouini A, Venue L, Slama KB et al. Characterization of CTX-M and
SHV extended-spectrum {beta}-lactamases and associated resistance
genes in Escherichia coli strains of food samples in Tunisia. J Antimicrob
Chemother 2007; 60: 1137–1141.
13. Diancourt L, Passet V, Verhorf J, Grimont PAD, Brisse S. Multilocus
sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin
Microbiol 2005; 43: 4178–4182.
14. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial disk susceptibility tests. Approved Standard, Ninth Edition.
M2-A9. Wayne, PA: CLSI, 2006.
15. Bertrand S, Weill FX, Cloeckaert A et al. Clonal emergence of
extended-spectrum b-lactamase (CTX-M-2)-producing Salmonella ent-
erica serovar Virchow isolates with reduced susceptibilities to cipro-
ﬂoxacin among poultry and humans in Belgium and France (2000 to
2003). J Clin Microbiol 2006; 44: 2897–2903.
16. Weill FX, Perrier-Gros-Claude JD, Demartin M, Coignard S, Grimont
PA. Characterization of extended-spectrum-beta-lactamase (CTX-M-
15)-producing strains of Salmonella enterica isolated in France and
Senegal. FEMS Microbiol Lett 2004; 238: 353–358.
17. Fevre C, Passet V, Weill FX, Grimont PAD, Brisse S. Variants of the
Klebsiella pneumoniae OKP chromosomal beta-lactamase are divided
into two main groups, OKP-A and OKP-B. Antimicrob Agents Chemo-
ther 2005; 49: 5149–5152.
18. Hammond DS, Schooneveldt JM, Nimmo GR, Huygens F, Giffard PM.
blaSHV Genes in Klebsiella pneumoniae: different allele distributions are
associated with different promoters within individual isolates. Antimic-
rob Agents Chemother 2005; 49: 256–263.
19. Kim J, Shin HS, Seol SY, Cho DT. Relationship between blaSHV-12 and
blaSHV-2a in Korea. J Antimicrob Chemother 2002; 49: 261–267.
20. Naas T, Philippon L, Poirel L, Ronco E, Nordmann P. An SHV-
derived extended-spectrum b-lactamase in Pseudomonas aeruginosa.
Antimicrob Agents Chemother 1999; 43: 1281–1284.
21. Saladin M, Cao VT, Lambert T et al. Diversity of CTX-M b-lactamas-
es and their promoter regions from Enterobacteriaceae isolated in
three Parisian hospitals. FEMS Microbiol Lett 2002; 209: 161–168.
22. Takahashi S, Nagano Y. Dissemination of gentamicin-resistant plas-
mids among strains of Enterobacteriacae. J Hosp Infect 1985; 6: 46–59.
CMI Elhani et al. ESBL-producing K. pneumoniae in Tunisia 163
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 157–164
23. Weill FX, Demartin M, Tande D, Espie E, Rakotoarivony I, Grimont
PAD. SHV-12-like extended-spectrum-b-lactamase-producing strains
of Salmonella enterica serotypes Babelsberg and Enteritidis isolated in
France among infants adopted from Mali. J Clin Microbiol 2004; 42:
2432–2437.
24. Barton BM, Harding GP, Zuccarelli AJ. A general method for detect-
ing and sizing large plasmids. Anal Biochem 1995; 226: 235–240.
25. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Iden-
tiﬁcation of plasmids by PCR-based replicon typing. J Microbiol Meth-
ods 2005; 63: 219–228.
26. Brisse S, Fevre C, Passet V et al. Virulent clones of Klebsiella pneumo-
niae: identiﬁcation and evolutionary scenario based on genomic and
phenotypic characterization. PLoS ONE 2009; 4: e4982.
27. Brisse S, Verhoef J. Phylogenetic diversity of Klebsiella pneumoniae and
Klebsiella oxytoca clinical isolates revealed by randomly ampliﬁed poly-
morphic DNA, gyrA and parC genes sequencing and automated ribo-
typing. Int J Syst Evol Microbiol 2001; 51: 915–924.
28. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing
the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165–
174.
29. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-pro-
ducing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii–19044.
30. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid mediated
extended-spectrum beta-lactamase (CTX-M-3 like) from India and
gene association with insertion sequence ISEcp1. FEMS Microbiol Lett
2001; 201: 237–241.
31. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally
related Escherichia coli strains expressing extended-spectrum beta-lac-
tamase CTX-M-15. Emerg Infect Dis 2008; 14: 195–200.
32. Damjanova I, To´th A, Pa´szti J et al. Expansion and countrywide dis-
semination of ST11, ST15 and ST147 ciproﬂoxacin-resistant CTX-M-
15-type beta-lactamase-producing Klebsiella pneumoniae epidemic
clones in Hungary in 2005—the new ‘MRSAs’? J Antimicrob Chemother
2008; 62: 978–985.
33. Lavollay M, Mamlouk K, Frank T et al. Clonal dissemination of a
CTX-M-15 b-lactamase-producing Escherichia coli strain in the Paris
area, Tunis, and Bangui. Antimicrob Agents Chemother 2006; 50: 2433–
2438.
34. Nicolas-Chanoine MH, Blanco J, Leﬂon-Guibout V et al. Interconti-
nental emergence of Escherichia coli clone O25:H4-ST131 producing
CTX-M-15. J Antimicrob Chemother 2008; 61: 273–281.
35. Iabadene H, Messai Y, Ammari H et al. Prevalence of plasmid-medi-
ated AmpC b-lactamases among Enterobacteriaceae in Algiers hospi-
tals. Int J Antimicrob Agents 2009; 34: 340–342.
36. Oteo J, Cuevas O, Lopez-Rodriguez I et al. Emergence of CTX-M-15-
producing Klebsiella pneumoniae of multilocus sequence types 1, 11,
14, 17, 20, 35 and 36 as pathogens and colonizers in newborns and
adults. J Antimicrob Chemother 2009; 64: 524–528.
37. Poirel L, Lartigue MF, Decousser JW, Nordmann P. ISEcp1B-mediated
transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemo-
ther 2005; 49: 447–450.
164 Clinical Microbiology and Infection, Volume 16 Number 2, February 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 157–164
